Vaxart's BARDA Deal: A Scaled-Down Trial Signals a High-Stakes Future

SOUTH SAN FRANCISCO, CA – June 25, 2026 – At first glance, the press release from Vaxart, Inc. reads like a mixed message wrapped in corporate optimism. The biotech firm announced a contract modification for its oral COVID-19 pill vaccine trial, a deal that simultaneously reduces the total potential government funding by over $100 million while releasing a crucial, smaller tranche of cash. In the world of high-stakes biotech development, such a move is never simple. It’s a signal, and reading it correctly requires looking past the headline figures to understand the intent of the key players: a small company with a potentially game-changing technology and a government agency planning for the next pandemic.

The announcement reveals that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has adjusted its support for Vaxart’s Phase 2b trial. While the total funding available has decreased to approximately $345 million, this latest change unlocks about $29 million. The purpose of this new cash injection? To complete the trial and, most importantly, fund “exploratory analyses” of the data. This is the crux of the matter. It’s a move that speaks volumes about BARDA’s shifting strategy and Vaxart’s perilous but promising journey.

A Complicated Partnership

To understand today’s news, one must look back at the turbulent history of Vaxart’s partnership with BARDA. In June 2024, the company secured a major award under Project NextGen—BARDA’s initiative to find innovative pandemic countermeasures—worth up to $453 million. The goal was ambitious: a 10,000-participant study to test its oral vaccine against an established mRNA shot. For a clinical-stage company trading on the OTCQX market, this was a monumental vote of confidence.

But the path forward was not smooth. Just over a year later, in August 2025, BARDA issued a partial termination order, effectively halving the trial’s enrollment size to around 5,000 participants. This decision, which Vaxart noted coincided with a broader HHS pullback from some mRNA vaccine development, slashed the potential funding by approximately $116 million and cast a shadow of uncertainty over the program. The government was recalibrating its bets in a post-pandemic world, and Vaxart was caught in the shift.

This week’s modification is the latest chapter in that complex relationship. It formally acknowledges the smaller trial size while providing the necessary resources to see it through to a meaningful conclusion. “This contract modification was a necessary step to unblinding and reporting the first set of data from our sentinel cohort,” said Steven Lo, Vaxart's CEO, underscoring the procedural importance of the deal. The move ensures that the significant investment already made—in enrolling over 5,000 people—is not wasted.

Reading the Data, and the Tea Leaves

The decision to reduce a trial’s size is never taken lightly. According to clinical trial design experts, halving a participant pool can impact a study's statistical power, making it more difficult to prove a vaccine’s efficacy with the high degree of certainty that regulators demand. While a cohort of 5,085 is still substantial, the change introduces a new layer of risk for Vaxart’s path to market.

This is why BARDA’s decision to now fund “deeper analytics” is so telling. It signals that the agency, despite scaling back the trial, has not lost interest in the underlying technology. Rather than simply completing the study on a shoestring, BARDA is investing in a comprehensive post-mortem. This suggests a strategic intent to extract every possible insight from the existing data. Is the vaccine effective in specific subgroups? Does it produce a unique immune response? These are the questions exploratory analyses can help answer, providing crucial intelligence for future vaccine development, even if this specific trial faces a higher regulatory bar.

This is classic portfolio management on a national scale. BARDA is balancing its budget and priorities, but it is unwilling to walk away from a technology that holds immense strategic promise. The agency is keeping its options open, gathering data on a novel platform that could one day be a cornerstone of its pandemic response arsenal.

The Promise and Peril of the Pill

Vaxart’s core value proposition lies in its delivery method. An effective oral pill vaccine would be nothing short of revolutionary. It would eliminate the need for cold-chain storage and distribution, a massive logistical hurdle that complicates vaccination campaigns in remote and underserved regions. It would also remove the need for needles, potentially overcoming vaccine hesitancy for a significant portion of the population and simplifying mass administration.

Scientifically, Vaxart’s platform aims to generate mucosal immunity—a first line of defense in the airways and gut where pathogens like SARS-CoV-2 enter the body. This is a key goal of next-generation vaccines, as it holds the potential to not only prevent severe disease but also to block transmission more effectively than current injectable vaccines.

This ambition aligns perfectly with the stated goals of Project NextGen, which has also awarded funding to companies like Castlevax and Cyanvac for intranasal vaccine candidates. The federal government is clearly looking beyond the needle. Vaxart is no longer just competing with Pfizer and Moderna; it is part of a broader strategic pivot towards more accessible and potentially more effective vaccine technologies. The question is whether its specific platform can deliver on that promise.

A High-Stakes Bet for a Small Biotech

For Vaxart, the stakes could not be higher. With a market capitalization hovering around $125 million and a cash runway projected into the second quarter of 2027, the company operates with a finite window of opportunity. The BARDA contract has been its financial lifeline. While the company holds more cash than debt, its future hinges on clinical success.

Investor sentiment has been a rollercoaster, mirroring the funding saga. The initial massive BARDA award in 2024 was followed swiftly by a stock offering that raised concerns about shareholder dilution. Today’s news brings both relief—the trial will yield data—and continued apprehension about the reduced scope.

The upcoming data releases are therefore pivotal. The 12-month results from the 400-participant sentinel cohort, expected in the coming weeks, will be the first major test. But all eyes are truly on the data from the main 5,085-participant cohort, due in the first half of 2027. A strong positive signal could validate the entire platform, unlock further partnerships, and send the company’s valuation soaring. Anything less could make securing future funding an immense challenge.

This funding modification, then, is not an endpoint but a trigger. It sets the stage for a data-driven verdict on a decade of research and development. It confirms that while the government's ambitions for this specific trial have been scaled back, its interest in the technology's potential remains, leaving Vaxart at a critical juncture where the coming results will determine its future.